Standard chemotherapy hits as hard as possible. Maximum tolerated dose: push the drug concentration to the edge of what the patient can survive, wait for recovery, hit again. The logic is simple — kill as many cancer cells as possible per cycle. Lopes, Rodrigues, and Pinho (arXiv: 2603.16894) model the alternative mathematically and show it wins.
Metronomic chemotherapy delivers drugs continuously at low doses instead of intermittently at high doses. Their ODE model tracks tumor cells, immune cells, and drug concentration. Under maximum tolerated dose, the tumor shrinks dramatically during treatment but rebounds between cycles as the immune system, also damaged by high-dose chemo, fails to control residual cells. Under metronomic dosing, the tumor shrinks slowly but continuously, and — critically — the immune system stays functional throughout. The sustained immune pressure prevents the rebound.
The through-claim: the rebound is the disease, not the tumor. Maximum tolerated dose optimizes for the wrong objective — minimum tumor size at any instant — while degrading the system that maintains long-term control. Metronomic dosing optimizes for the right objective — sustained suppression — by keeping the immune system operational. The tumor is never as small as it gets under maximum dose, but it never rebounds either.
This is the same pattern as aggressive trading strategies that maximize per-trade profit while destroying bankroll stability: optimizing the instantaneous metric degrades the trajectory metric. The chemotherapy that looks weaker at any snapshot produces better outcomes over time because it preserves the system's own corrective capacity.
Lopes, Rodrigues & Pinho, 2603.16894. Mathematical oncology / chemotherapy / immune dynamics / optimization.